How can the use of CAR T-cell and checkpoint blockade strategies be optimized in order to cure hematologic diseases?
CAR therapy has resurrected the role of immunotherapy in treating cancer. But it has significant toxicity. Can we train , standardize the care of and adequately oversee the care of patients getting CAR therapy , especially as company begin to approach FDA for approval of this therapy and up scale for mass treatment.
Highly active antiretroviral therapy (HAART), while clearly invaluable, does not halt growth or proliferation of HL, in fact, while AIDS-defining malignancies like Kaposi’s sarcoma (KS) and non-Hodgkin’s lymphoma (NHL) have declined thanks to HAART, the incidence of HL in HIV patients has actually increased, from 14 times higher than that of non-HIV patients in the pre-HAART era to 32 times higher in the HAART era. Typical ...more »
As the current chair of the Research and Training Division, I would like to convey that the AAAAI membership would like the NHLBI to consider the following in the development of its strategic plan: What role should sublingual immunotherapy play in the treatment of asthma?
How can the effectiveness of existing curative therapies be improved for allogeneic hematopoietic stem cell transplantation?